Analyser av SenzaGen

SenzaGen Q1: Quarterly sales impacted by challenging market climate - Redeye

Redeye provides an update following SenzaGen’s Q1 2025 report.

Redeye • 15 maj 2025 07:27

SenzaGen: Q1 Initial take – Sales a bit lower than estimated - Redeye

Redeye provides an initial take following the release of SenzaGen’s Q1 2025 report.

Redeye • 14 maj 2025 08:54

SenzaGen: Expanded testing portfolio - Redeye

Redeye comments on SenzaGen’s expanded testing portfolio, introducing the EpiSensA method, which complements its current GARDskin test.

Redeye • 10 apr 2025 12:35

SenzaGen Q4: Leaving Q4 behind and looking forward to a new year - Redeye

Redeye provides an update following SenzaGen’s Q4 2024 report.

Redeye • 14 feb 2025 07:12

SenzaGen Q4 Initial take – Soft sales but solid cost control - Redeye

Redeye provides an initial take following the release of SenzaGen’s Q4 2024 report.

Redeye • 13 feb 2025 10:46

SenzaGen Q3: A solid quarter - Redeye

Redeye provides an update following SenzaGen’s Q3 2024 report.

Redeye • 11 nov 2024 07:28

SenzaGen: Grant worth SEK3.0m from RIFM - Redeye

Redeye endorses SenzaGen’s new grant from RIFM, valued at SEK3.

Redeye • 10 sep 2024 11:55

SenzaGen Q2: Continued sales growth - Redeye

Redeye provides an update following SenzaGen’s Q2 2024 report.

Redeye • 23 aug 2024 07:32

SenzaGen: SEK1.5m grant from RIFM - Redeye

Redeye endorses SenzaGen’s continued collaboration with RIFM.

Redeye • 04 jul 2024 07:31

SenzaGen: Directed issue - Redeye

Redeye comments on SenzaGen’s directed issue, raising SEK37.

Redeye • 13 jun 2024 15:01

SenzaGen Q1: Solid sales and EBITDA break even - Redeye

Redeye provides an update following SenzaGen’s Q1 report.

Redeye • 16 maj 2024 07:17

SenzaGen: Bra position in i 2024 - Penser Access by Carnegie

Förtroendegivande avslutning på 2023 Senzagen presterade starkt i Q4(23) med en nettoomsättning som steg med 26% Y/Y och under H2(23) var de...

Penser • 15 feb 2024 10:10

SenzaGen H2: Continued growth and aligned with our expectations - Redeye

Redeye provides an update in relation to SenzaGen’s H2 2023 report.

Redeye • 15 feb 2024 07:28

SenzaGen H2: Initial take on H2 2023 results – a solid half-year - Redeye

Redeye provides an initial take on SenzaGen’s H2 2023 report.

Redeye • 14 feb 2024 09:05

SenzaGen: GARDskin order from chemical company - Redeye

Redeye is positive about SenzaGen’s GARDskin order worth SEK1.

Redeye • 10 jan 2024 10:42

SenzaGen: Order from a global biotech industry leader - Redeye

Redeye endorses SenzaGen’s new order from a global biotech industry leader.

Redeye • 18 dec 2023 11:09

SenzaGen: Q3 2023 sales update - Redeye

Redeye comments on SenzaGen’s Q3 2023 sales update.

Redeye • 25 okt 2023 11:52

SenzaGen: På väg mot kassaflödesneutralitet - Penser

EBITDA förbättrades Koncernens nettoomsättning uppgick under perioden januari–juni 2023 till 23,6 mkr (19,9), en ökning med 18 % i jämförels...

Penser • 25 aug 2023 11:09

SenzaGen H1 2023: Initial take on H1 2023 results - Redeye

Redeye provides an initial take on SenzaGen’s H1 2023 report.

Redeye • 24 aug 2023 08:58

SenzaGen: Giftfri tillväxt - Penser

Starkt produkterbjudande SenzaGen erbjuder högpresterande djurfria testmetoder samt innovations- och konsulttjänster baserade på den senaste...

Penser • 04 maj 2023 11:02

SenzaGen: Q1 2023 sales update - Redeye

Redeye comments on SenzaGen’s Q1 2023 sales update, where sales during the first quarter amounted to SEK12.

Redeye • 26 apr 2023 12:55

SenzaGen: The beginning of the OECD effect - Redeye

Redeye endorses SenzaGen’s new GARDskin order of SEK1m from a new customer within the chemical industry.

Redeye • 23 feb 2023 09:54

SenzaGen H2 2022: In the right direction - Redeye

Redeye provides an update in relation to SenzaGen’s H2 2022 report.

Redeye • 17 feb 2023 09:03

SenzaGen H2 2022: Initial take on H2 2022 results - Redeye

Redeye provides an initial take on SenzaGen’s H2 2022 report.

Redeye • 16 feb 2023 10:46

SenzaGen: ToxHub strengthens SenzaGen’s offering - Redeye

Redeye is positive about SenzaGen’s acquisition of ToxHub, an Italian toxicology services company specializing in toxicological risk assessm...

Redeye • 14 nov 2022 11:39

SenzaGen: Acquisition of ToxHub - Redeye

Redeye provides a short comment on SenzaGen’s acquisition of ToxHub, an Italian toxicology services company specializing in toxicological ri...

Redeye • 11 nov 2022 16:12

SenzaGen: Continued Sales Growth in Q3 - Redeye

Redeye comments on SenzaGen’s Q3 sales update with total sales of SEK9m.

Redeye • 26 okt 2022 11:18

SenzaGen H1’22: Sales beat our estimates - Redeye

Redeye provides its comments on SenzaGen’s 2022 half-year report.

Redeye • 19 aug 2022 07:42

SenzaGen: New GARDskin order - Redeye

Redeye embraces the new GARDskin order of approximately SEK 1m.

Redeye • 11 aug 2022 14:12

SenzaGen: OECD Approval for GARDskin - Redeye

Redeye embraces the news regarding the OECD validation on GARDskin.

Redeye • 30 jun 2022 11:41

SenzaGen: Large GARDskin Dose-Response Order - Redeye

Redeye endorses the news that SenzaGen has received its largest order so far with a value of SEK 4.

Redeye • 22 jun 2022 09:47

SenzaGen: The Non-Animal Alternative - Redeye

Redeye initiates coverage of SenzaGen, a Swedish commercial-stage MedTech company offering high-performance in-vitro technology tests that a...

Redeye • 05 maj 2022 07:40